Sep. 23,
For more information, please visit our website.
Pharmaceutical intermediates are fine chemicals that are intermediate compounds produced during the production of active pharmaceutical ingredients (APIs). Intermediates are the by-products of the reactions in the API production process. Each reaction in the production process may produce several intermediates, depending on the analysis, which can be used as precursors for other active pharmaceutical ingredients. The conversion of intermediates to active ingredients can be achieved by further refinement processes. Like APIs, intermediates can also be used as APIs for therapeutic purposes.
4-Chloro-2,6-diaminopyrimidine CAS No.: 156-83-2 is used as an intermediate of the drug Minoxidil, also used in organically synthesized compounds. α-Lipoic Acid CAS No.: -28-7 is used as an intermediate of vitamin drugs, can stimulate fat metabolism. It is used for the treatment of acute and chronic hepatitis, liver cirrhosis, hepatic coma, fatty liver, diabetes, and other diseases.
API (Active Pharmaceutical Ingredient) refers to the active ingredient contained in a drug. For example, a painkiller contains an active ingredient that relieves pain. A small amount of the active ingredient has an effect, so the drug contains only a very small amount of the active ingredient. You can find the name and quantity of the active ingredient in medicine on the packaging of OTC (over-the-counter) medicines.
α-Lipoic Acid CAS No.: -28-7
API and raw material are often confused due to the similar usage of these two terms. What is the difference? The raw material is a compound that is used as the basis for making an API. an API is not made from raw material by just one reaction, but by a variety of compounds that become API. the compounds that are being transformed from raw materials into APIs are called intermediates. Some APIs go through more than ten intermediates in the process of going from raw material to API.
What is the difference between an API and a pharmaceutical intermediate? These terms can be confusing and used interchangeably, especially by those new to the pharmaceutical industry. Although both APIs and intermediates have pharmacological activity, they differ in function, composition, and structure.
4-Chloro-2,6-diaminopyrimidine CAS No.: 156-83-2
Many factors and analyses distinguish active ingredients and compounds from pharmaceutical intermediates. Active ingredients and specialty chemicals are the end products of raw materials, while chemical intermediates are by-products of the API manufacturing process. Unlike APIs, which are usually safe and properly studied for therapeutic purposes, intermediates may be therapeutic, toxic, or even APIs. however, APIs produced as by-products cannot be administered or used as active ingredients without official approval. In addition, unlike active ingredients containing special chemicals, intermediates do not require approval or regulation to be used.
The pharmaceutical industry is constantly evolving and reinventing itself. A number of pharmaceutical companies and market players are adapting to innovations in the sale of pharmaceutical intermediates, as the demand for them is increasing rapidly. The growth in demand is the result of a combination of factors such as the surge in chronic diseases, which is having a positive impact on the size of the global pharmaceutical intermediates market. As global pharmaceutical activity increases, innovations are being born and demand for pharmaceutical intermediates manufacturers is on the rise. The global pharmaceuticals and packaging market has experienced a surge due to the implementation of regulated pharmaceutical activities, Good Manufacturing Practices (GMP) by pharmaceutical companies.
Qinmu is a Chinese pharmaceuticals supplier. Our chemical company can provide you with professional pharmaceuticals intermediates. If you have a demand for pharmaceutical raw materials, please contact us, we will provide you with the corresponding solutions as soon as possible.
6
SHARES
Mandybio International Product Page
Posted: 21 May | Smita Deshmukh (Transparency Market Research) |
Smita Deshmukh describes the current state of the global drug intermediates market, while suggesting how it will grow in the future.
Drug intermediates are used as raw materials during the manufacture of bulk drugs. These intermediates can also be referred to as the material produced at the time of synthesis of an active pharmaceutical ingredient (API). However, the API must undergo additional molecular processing or changes before becoming a final product.
Drug intermediates are generally hygienically formulated. Superior grade raw materials are used for their production and these are applied in both the cosmetic and pharmaceutical industries. Companies operating in the pharmaceutical industry can make use of these drug intermediates for the purposes of R&D.
There are several types of intermediates used in pharma such as bulk drug intermediates, veterinary drug intermediates and pharmaceutical intermediates.
In recent years, the global drug intermediates market has been witnessing a promising growth, driven by the growing demand from different end-use application industries.
The global market for drug intermediates is segmented in terms of type of intermediates, end user application industry and geography. There are two main types of drug intermediates called advanced intermediate and APIs. APIs, as aforementioned, are used as intermediate raw material for the production of therapeutic drugs. These are active ingredients that are later converted into different forms such as suspensions, capsules, tablets and other formulations. Therefore, the API itself acts as a drug.
On the other hand, advanced ingredients are the advanced form of drug intermediates. There are several different types of advance intermediates such as imatinib intermediates, Capecitabine intermediates, pemetrexed intermediates, lenalidomide intermediates, gemcitabine intermediates, afatinib intermediates, nilotinib intermediates, temozolomide intermediates, pazopanib intermediates and ibrutinib intermediates.
In terms of end user, the global market for drug intermediates can be split into chemical industry, biotechnology and pharmaceutical industry. There are several different forms of drug intermediates available such as premium quality intermediates, high quality intermediates and moderate quality intermediates. The premium and high-quality intermediates are mainly used for R&D activities.
There have been increasing requirements for drug intermediates in the international market because of the rapid developments and advancements happening in the life sciences and biotechnology fields. In addition to this, there has been a growing adoption and rising applications of drug intermediates in the field of research and clinical studies. Companies operating in the pharmaceutical and biotechnology sectors along with research institutes are now increasingly focusing on R&D activities relating to drug creation and development. They are also paying special attention to creating new techniques and methods along with equipment for the synthesis of drug intermediates. In the future, this will offer manufacturers the flexibility to provide high levels of customisation in synthesised drugs. Moreover, it has helped in increasing the scope of its broad ranging applications and has thus helped in the overall development of the global drug intermediates market.
In terms of geographical classification, the global drug intermediates market has been segmented into five key regions. These regional segments are North America, Asia Pacific, Middle East and Africa, Latin America and Europe. Currently, the global market is being led by the regional segment of Asia Pacific. The growth of the regional market is mainly attributed to developments and advancements in the field of life sciences and biotechnology. Moreover, increased levels of spending and backing provided by the emerging nations such as India and China for carrying out new research studies and drug synthesis processes has also helped the overall development of the Asia Pacific market.
Some of the prominent brands in the global drug intermediate market include Ami Lifesciences, Accrete Pharmaceuticals Pvt. Ltd, A.B. Enterprises, Ramdev Chemicals Pvt. Ltd., Clearsynth, Aarti Drugs Ltd., Synpure Labs and Karvy Therapeutics Pvt. Ltd, among others.
Click here to find the report.
Smita Deshmukh is a Team Lead at Transparency Market Research, a firm based in India and the US. She is a digital marketing professional with more than five years' experience and has a Bachelor's Degree in Computer Science and a Master's degree in Business Administration.